Tadalafil
ADCIRCA, ALYQ, Cialis, TADLIQ
Phosphodiesterase 5 Inhibitor
NADAC/unit
$0.1044
No Shortage
Tier 1: 66.9%
PA Req: 321.3%
28 Manufacturers
111 ANDAs
Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the....
vs. brand ADCIRCA: Generic saves up to 99% per unit
Market Intelligence
2023-05-03 Class II Recall: Northwind Pharmaceuticals LLC
2023-05-03 Class II Recall: Northwind Pharmaceuticals LLC
2023-04-12 Class II Recall: Preferred Pharmaceuticals, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
Generic Manufacturers
ACCORD HEALTHCARE INCAJANTA PHARMA LTDALEMBIC PHARMACEUTICALS LTDAMNEAL PHARMACEUTICALS CO GMBHAUROBINDO PHARMA LTDCHARTWELL RX SCIENCES LLCCIPLA LTDCMP DEVELOPMENT LLCDR REDDYS LABORATORIES LTDELI LILLY AND COELI LILLY COFOURRTS INDIA LABORATORIES PRIVATE LTDHANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTDHETERO LABS LTD UNIT IIILUPIN LTDMACLEODS PHARMACEUTICALS LTDNOVITIUM PHARMA LLCPRINSTON PHARMACEUTICAL INCQILU PHARMACEUTICAL HAINAN CO LTDSHANDONG NEW TIME PHARMACEUTICAL CO LTDSUN PHARMACEUTICAL INDUSTRIES LTDSUNSHINE LAKE PHARMA CO LTDTEVA PHARMACEUTICALS INCTEVA PHARMACEUTICALS USATEVA PHARMACEUTICALS USA INCTORRENT PHARMACEUTICALS LTDUMEDICA LABORATORIES PRIVATE LTDUNICHEM LABORATORIES LTDVKT PHARMA PRIVATE LTDWATSON LABORATORIES INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.